Efgartigimod for Guillain-Barré Syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if the drug efgartigimod can help people with Guillain-Barré Syndrome (GBS). If you have had GBS symptoms for less than two weeks and your weakness is moderate to severe, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Guillain-Barré Syndrome (GBS) by your doctor.
- Your GBS symptoms started within the last 2 weeks.
- Your weakness is rated as moderate to severe (score 3 to 5 on the GBS Disability Scale).
- You are not allergic to efgartigimod or similar drugs.
- You do not have an active infection or another autoimmune disease that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at people who were suspected to have Guillain-Barré syndrome and were cared for at University Hospital of Basel in the past. It does not test a new treatment—researchers review existing care to learn more about this condition.
This study compares immunoadsorption (a blood-filtering treatment) versus intravenous immunoglobulin (IVIG) to see which works better and is safer for Guillain-Barré syndrome. It may help you by testing treatments commonly used to reduce nerve damage and improve recovery.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
This study tests whether immunoadsorption works as well as plasma exchange to improve symptoms in people with Guillain-Barré syndrome. The goal is to find which treatment helps recovery and is safer for patients.
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Hear when a new Guillain-Barre Syndrome (GBS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.